Evidence map›Paper›PMID 33112715›Full record

ArticleRadiology2021

Imaging the Immune Tumor Microenvironment to Monitor and Improve Therapy.

Gary D Luker

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Gary D LukerFrom the Department of Radiology, University of Michigan, 109 Zina Pitcher Pl, A524 BSRB, Ann Arbor, MI 48109-2200.ORCID 0000-0001-6832-2581

Funding

Interstitial Fluid Flow Regulates Glioma Cell InvasionR37CA222563 · NCI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI MUNSON, JENNIFER M · 2018 to 2024
$4.0M
Environmental Regulation of Cancer Stem Cell Plasticity in MetastasisU01CA210152 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAHANN, JOERG, LUKER, GARY D · 2017 to 2021
$3.6M
University of Michigan Quantitative Co-Clinical Imaging Research ResourceU24CA237683 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHENEVERT, THOMAS L, LUKER, GARY D · 2019 to 2023
$3.1M
Imaging Disease Heterogeneity and Response to Therapy in MyelofibrosisR01CA238023 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUKER, GARY D, ROSS, BRIAN D. · 2019 to 2023
$3.1M
Integrators of Metastatic PotentialR01CA238042 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, LUKER, GARY D · 2019 to 2023
$2.3M
Systems Bioengineering of Cancer Cell MigrationR01CA196018 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LINDERMAN, JENNIFER JEAN, LUKER, GARY D · 2015 to 2019
$2.2M
A High Throughput Human Tumor Modeling Technology for Cancer Drug DiscoveryR33CA225549 · NCI · UNIVERSITY OF AKRON · PI LUKER, GARY D, TAVANA, HOSSEIN · 2019 to 2021
$1.4M
NCI NIH HHS R01 CA196018NCI NIH HHS R01 CA238023NCI NIH HHS R01 CA238042NCI NIH HHS R33 CA225549NCI NIH HHS R37 CA222563NCI NIH HHS U01 CA210152NCI NIH HHS U24 CA237683
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsThyroid Carcinoma, AnaplasticThyroid NeoplasmsFerrosoferric OxideHumansImmunityMagnetic Resonance ImagingProto-Oncogene Proteins B-rafTumor MicroenvironmentBRAF protein, humanFerrosoferric OxideProto-Oncogene Proteins B-raf

Identifiers

PMID33112715
PMCPMC7771989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.